Biotech | September 08, 2021
Biocon settles suit with Celgene for generic Revlimid
Revlimid is a blood cancer drug with sales of US $ 12.1 billion in 2020
Revlimid is a blood cancer drug with sales of US $ 12.1 billion in 2020
Takeda is establishing the capability to manufacture TAK-019 (known outside Japan as NVX-CoV2373) at its facilities in Japan and aims to begin distribution in the early calendar year 2022
The lab will offer over 4,000 clinical tests and profiles and can conduct over 20,000 sample tests per month.
The study is being carried out by the platform VISION (Vaccine Immunology Studies – Indian Outbreak-response Network) which includes top public and private research institutes.
Amptron’s R &D is based out of the US and this will enable Max to obtain US and other global certifications. Max will retain the right to market, sell and distribute the products in India.
In March 2016, Dr. Reddy’s had acquired the exclusive global rights (excluding Japan and Asia) to the investigational anti-cancer agent E7777 from Eisai Co.
The Stasis connected care monitoring system includes - a bedside monitor that monitors 6 vital signs, a tablet that enables intuitive monitoring, and the Stasis app that allows for remote monitoring across devices
_256_384.jpeg)
The company aims to continue its expansion via organic and inorganic routes to increase production capacity and product portfolio
JADE DARE trial met co-primary and key secondary endpoints and demonstrated a safety profile consistent with previous studies for moderate to severe atopic dermatitis
Blood samples were collected from 114 healthcare workers who received Covaxin in Chennai from February to May 2021
Subscribe To Our Newsletter & Stay Updated
